Notice of AGM

Summary by AI ^BETAClose X

ProBiotix Health plc has announced its Annual General Meeting will be held on 23 June 2026 at 11:00 am, where the accounts for the year ending 31 December 2025 will be presented. The company, which develops probiotics for cardiometabolic health, will make the AGM notice and financial statements available on its website shortly.

Disclaimer*

Probiotix Health PLC

29 May 2026

ProBiotix Health plc

("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")

Notice of Annual General Meeting

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce that Notice convening the Company's Annual General Meeting for 11:00 am on 23 June 2026 at the offices of AlbR Capital Limited, 3^rd Floor 80 Cheapside, London EC2V 6EE. The accounts for the year to 31 December 2025, and the Notice of AGM will be available on the Company's website at www.probiotixhealth-ir.com shortly.

For further information, please contact:

ProBiotix Health plc	https://probiotixhealth-ir.com/
	investors@probiotixhealth.com
Steen Andersen, Chief Executive Officer Miles Nolan, Investor Relations

AlbR Capital Limited Aquis Corporate Adviser and Broker
David Coffman Dan Harris	Tel: 020 7469 0930

Notes to Editors:

ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.

The Company has a unique approach: discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END